[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology].
Imipenem (MK-0787), a new carbapenem antibiotic, combined with cilastatin sodium (MK-0791), was studied clinically and microbiologically. The following results were obtained: Concentrations of MK-0787 in the plasma and internal genital tissues were measured at 1 hour after an intravenous drip infusion of MK-0787/MK-0791 (500 mg/500 mg) for 30 minutes. Mean plasma levels higher than 11.8 micrograms/ml and mean tissue levels higher than 2.3 micrograms/g were observed. When its MIC values are considered, MK-0787/MK-0791 appeared to be bactericidal against many Gram-positive and Gram-negative bacteria except some Pseudomonas sp. and Enterococcus faecium. Clinical effects of the therapy with MK-0787/MK-0791 (500 mg/500 mg) using a drip infusion twice daily were evaluated in 3 patients with pyometra and 3 patients with Bartholin's gland abscess. Clinical responses were good in 5 of the 6 patients. One patient with pyometra due to E. coli didn't respond to the therapy. No side effects or abnormal laboratory findings due to the drug were noted.
Nakanishi
A
A
Hino
K
K
Shimamoto
I
I
Ichijo
M
M
D000038:Abscess / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D001472:Bartholin's Glands; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000378:metabolism; D004338:Drug Combinations; D004716:Endometritis / Q000188:drug therapy*; D005260:Female; D005836:Genitalia, Female / Q000378:metabolism; D006801:Humans; D015378:Imipenem; D008875:Middle Aged; D013492:Suppuration; D013845:Thienamycins / Q000008:administration & dosage* / Q000378:metabolism
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem